Q3 2016 13F Holders as of 30 Sep 2016
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
74,361,296
-
Number of holders
-
44
-
Total 13F shares, excl. options
-
16,266,787
-
Shares change
-
-1,066,852
-
Total reported value, excl. options
-
$267,555,203
-
Value change
-
-$17,049,726
-
Number of buys
-
20
-
Number of sells
-
-17
-
Price
-
$16.45
Significant Holders of Corvus Pharmaceuticals, Inc. - Common Stock (CRVS) as of Q3 2016
51 filings reported holding CRVS - Corvus Pharmaceuticals, Inc. - Common Stock as of Q3 2016.
Corvus Pharmaceuticals, Inc. - Common Stock (CRVS) has 44 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 16,266,787 shares
of 74,361,296 outstanding shares and own 21.88% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (5,379,349 shares), Novo A/S (3,224,046 shares), ADAMS STREET PARTNERS LLC (2,687,381 shares), FMR LLC (1,029,800 shares), PRICE T ROWE ASSOCIATES INC /MD/ (638,297 shares), JENNISON ASSOCIATES LLC (569,327 shares), BlackRock Advisors LLC (456,117 shares), Rock Springs Capital Management LP (450,000 shares), SPHERA FUNDS MANAGEMENT LTD. (325,053 shares), and venBio Select Advisor LLC (268,369 shares).
This table shows the top 44 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.